# OnCo record treatment-induced-diarrhoea-grading-and-management (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/treatment-induced-diarrhoea-grading-and-management/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "treatment-induced-diarrhoea-grading-and-management" ;
  schema:name "Diarrhoea from chemotherapy, targeted therapy and radiotherapy: grading, loperamide, octreotide and when to admit"@en ;
  schema:alternateName "chemotherapy-induced diarrhoea"@en, "CID"@en, "cancer treatment-induced diarrhea"@en, "loperamide for chemotherapy diarrhoea"@en, "octreotide for chemotherapy diarrhoea"@en, "complicated diarrhoea"@en ;
  schema:description "Treatment diarrhoea can turn dangerous quickly, especially with a low blood count. Drink plenty and start loperamide at the first loose stool if your team has told you to. Call the 24-hour line at once if it does not settle within a day, if there are seven or more stools a day, or with fever, blood, vomiting or dizziness. If cancer tablets are the cause and loperamide fails, stop them and ring."@en ;
  schema:url <https://onco.cc/protocols/treatment-induced-diarrhoea-grading-and-management/> ;
  schema:dateModified "2026-11-11"^^xsd:date ;
  onco:tag "protocol", "diarrhoea", "supportive-care" ;
  onco:related <https://onco.cc/protocols/irinotecan-early-cholinergic-syndrome-and-late-diarrhoea/>, <https://onco.cc/protocols/neratinib-diarrhoea-prophylaxis-and-dose-escalation/>, <https://onco.cc/drugs/octreotide-lanreotide/>, <https://onco.cc/protocols/febrile-neutropenia-first-hour/> ;
  onco:sections <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/probiotics-treatment-diarrhoea/>, <https://onco.cc/technologies/bowel-after-pelvic-radiotherapy/> ;
  onco:drugs <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/irinotecan/>, <https://onco.cc/drugs/sacituzumab-govitecan/>, <https://onco.cc/drugs/idelalisib/>, <https://onco.cc/drugs/pertuzumab/>, <https://onco.cc/drugs/panitumumab/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/sorafenib/> ;
  onco:institutions <https://onco.cc/institutions/nci/>, <https://onco.cc/institutions/mascc/>, <https://onco.cc/institutions/esmo/> ;
  onco:terms <https://onco.cc/terms/ctcae-grading/>, <https://onco.cc/terms/immune-colitis/>, <https://onco.cc/terms/febrile-neutropenia/> .